US008642012B2

(12) **United States Patent**
Scharschmidt

(10) **Patent No.: US 8,642,012 B2**
(45) **Date of Patent: Feb. 4, 2014**

(54) **METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS**

(75) Inventor: **Bruce Scharschmidt**, South San Francisco, CA (US)

(73) Assignee: **Hyperion Therapeutics, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 623 days.

(21) Appl. No.: **12/350,111**

(22) Filed: **Jan. 7, 2009**

(65) **Prior Publication Data**

US 2010/0008859 A1 Jan. 14, 2010

Related U.S. Application Data

(60) Provisional application No. 61/093,234, filed on Aug. 29, 2008.

(51) **Int. Cl.**
A61K 49/00 (2006.01)

(52) **U.S. Cl.**
USPC **424/9.2**; 514/568; 514/432; 514/433

(58) **Field of Classification Search**
USPC 424/9.2
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,284,647	A	8/1981	Brusilow et al.	
5,968,979	A	10/1999	Brusilow	
6,060,510	A	5/2000	Brusilow	
6,083,984	A *	7/2000	Brusilow	514/533
6,219,567	B1	4/2001	Eggers et al.	
2004/0229948	A1	11/2004	Summar et al.	
2006/0135612	A1	6/2006	Ferrante	
2008/0119554	A1	5/2008	Jalan et al.	
2010/0008859	A1	1/2010	Scharschmidt	

FOREIGN PATENT DOCUMENTS

WO	WO-2005/053607		6/2005
WO	WO-2006/056794		6/2006
WO	WO-2009/087474		7/2009
WO	WO-2009/134460	A1	11/2009
WO	WO-2010/250303	A1	3/2010

OTHER PUBLICATIONS

Berry et al., J Pediatrics (2001) 138:S56-S61.
Brusilow, Pediatric Research (1991) 29:147-150.
Brusilow, Progress in Liver Diseases (1995) 12:293-309.
Brusilow and Finkelstein, J Metabolism (1993) 42:1336-1339.
Chang et al., PNAS USA (2001) 98(17):9808-9813.
FDA Label for Buphenyl, 6 pages.
Kasumov et al., Drug Metabolism and Disposition (2004) 32(1):10-19.
Rudman et al., J Clin Invest (1973) 52:2241-2249.
Singh, Suppl to J Pediatrics (2001) 138(1):S1-55.
Thibault et al., Cancer (1995) 75(12):2932-2938.
Thibault et al., Cancer Research (1994) 54(7):1690-1694.
International Search Report and Written Opinion for PCT/US09/30362, mailed Mar. 2, 2009, 8 pages.
ClinicalTrials.Gov/Archive View of NCT00551200 on Dec. 11, 2007 "Dose-Escalation Safety Study of Glyceryl Tri (4-Phenylbutyrate)(GT4P) to Treat Urea Cycle Disorders" [accessed Oct. 5, 2009], 4 pages.
Comte et al., Journal of Mass Spectrometry (2002) 37(6):581-590.
Lee et al., Journal of Inherited Metabolic Disease (2008) 31(1):91.
Search and Examination Report for British Patent Application No. GB 0915545.8, dated Oct. 8, 2009, 5 pages.
MacArthur et al. (2004). Molecular Genetics and Metabolism 81(1):S67-S73.
Simmell et al. (1986). Pediatric Research 20(11):1117-1121.
Tanner et al. (2007). Journal of Inherited Metabolic Disease 30(5):716-721.
International Search Report and Written Opinion for PCT/US2009/055256, mailed Dec. 30, 2009, 13 pages.
Ambrose, A.M. et al. (1933)."Further Studies on the Detoxification of Phenylacetic Acid.," *J. Biol. Chem.* 101:669-675.
Batshaw M.L. et al. (Dec. 1980). "Treatment of Hyperammonemic Coma Caused by Inborn Errors of Urea Synthesis," *J. Pediatr.* 97(6):893-900.
Batshaw, M.L. et al. (Aug. 1981). "New Approaches to the Diagnosis and Treatment of Inborn Errors of Urea Synthesis," *Pediatrics* 68(2):290-297.
Batshaw M.L. et al. (Jun. 10, 1982). "Treatment of Inborn Errors of Urea Synthesis: Activation of Alternative Pathways of Waste Nitrogen Synthesis and Excretion," *N. Engl. J. Med.* 306(23):1387-1392.
Batshaw, M.L. (1984). "Hyperammonemia," in *Current Problems in Pediatrics*, Lockhart, J.D. ed.: Year Book Medical Publishers, pp. 2-69.
Brusilow, S.W. et al. (Sep. 1, 1979). "New Pathways of Nitrogen Excretion in Inborn Errors of Urea Synthesis," *Lancet* 2(8140):452-454.
Brusilow, S. et al. (Feb. 8, 1980). "Amino Acid Acylation: A Mechanism of Nitrogen Excretion in Inborn Errors of Urea Synthesis," *Science* 207:659-661.
Brusilow, S.W. (Jun. 21, 1984). "Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis," *N. Engl. J. Med.* 310(25):1630-1634.
Brusilow, S.W. et al. (1991). "Treatment of Urea Cycle Disorders," Chapter 5 in *Treatment of Genetic Diseases*, Desnik, R.J. et al. eds, Churchill Livingstone, New York, New York, pp. 79-94.

(Continued)

Primary Examiner — Jon P Weber
Assistant Examiner — Tiffany Gough
(74) *Attorney, Agent, or Firm* — Perkins Coie LLP; Patrick Morris

(57) **ABSTRACT**

The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.

12 Claims, 15 Drawing Sheets